Peterson Kristine — SEC Form 4 filings
SEC reporting owner CIK 1508596. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-02-12 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 19.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ImmunoGen, Inc. (IMGN) | Director | 1 | — | — | 10 |
| ArriVent BioPharma, Inc. (AVBP) | Director | 3 | — | — | 3 |
| ENANTA PHARMACEUTICALS INC (ENTA) | Director | 3 | — | — | 3 |
| Immunocore Holdings plc (IMCR) | Director | 3 | — | — | 3 |
Form 4 filings — Peterson Kristine
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 13,562 (derivative) @ $0 | EDGAR |
| 2026-05-28 | 4 | Immunocore Holdings plc (IMCR) | Grant/award (A): 27,492 (derivative) @ $0 | EDGAR |
| 2026-03-13 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 15,502 (derivative) @ $0 | EDGAR |
| 2025-05-19 | 4 | Immunocore Holdings plc (IMCR) | Grant/award (A): 26,198 (derivative) @ $0 | EDGAR |
| 2025-03-14 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Immunocore Holdings plc (IMCR) | Grant/award (A): 14,534 (derivative) @ $0 | EDGAR |
| 2024-04-23 | 4 | ArriVent BioPharma, Inc. (AVBP) | Grant/award (A): 28,587 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | ENANTA PHARMACEUTICALS INC (ENTA) | Grant/award (A): 15,700 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | ImmunoGen, Inc. (IMGN) | Disposition to issuer (D): 13,090 (derivative) · Disposition to issuer (D): 74,954 (derivative) · Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 10,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · Disposition to issuer (D): 18,000 (derivative) · +4 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1508596 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →